BioPharma Provides $150MM Royalty-Backed Debt Financing to Halozyme
Halozyme Therapeutics entered into a $150 million royalty-back debt financing with BioPharma Credit Investments as collateral agent and lender and Athryrium Capital Management as lender.
January 6, 2016
Athyrium Capital Managment | Halozyme Therapeutics | Pharmakon Advisors
ABF Journal